Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Majellaro

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Pharmacological Research|November 10, 2021
Similarities and differences upon binding of naturally occurring Δ<sup>9</sup>-tetrahydrocannabinol-derivatives to cannabinoid CB<sub>1</sub> and CB<sub>2</sub> receptorsIu Raïch, Rafael Rivas-Santisteban, Alejandro Lillo, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 26, 2023
Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugsClaudia Gioé-Gallo, Sandra Ortigueira, José Brea, et al.
Journal of Medicinal Chemistry|June 24, 2020
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A<sub>2B</sub> Adenosine Receptor AntagonistsAna Mallo-Abreu, Rubén Prieto-Díaz, Willem Jespers, et al.
Journal of Medicinal Chemistry|June 10, 2021
Potent and Subtype-Selective Dopamine D<sub>2</sub> Receptor Biased Partial Agonists Discovered via an Ugi-Based ApproachAna Mallo-Abreu, Irene Reyes-Resina, Jhonny Azuaje, et al.
European Journal of Medicinal Chemistry|January 19, 2023
N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R)Giovanni Graziano, Pietro Delre, Francesca Carofiglio, et al.
Angewandte Chemie (International Ed. in English)|June 17, 2020
X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A<sub>2A</sub> Adenosine Receptor AntagonistsWillem Jespers, Grégory Verdon, Jhonny Azuaje, et al.
ACS Medicinal Chemistry Letters|February 18, 2022
Exploring Non-orthosteric Interactions with a Series of Potent and Selective A<sub>3</sub> AntagonistsDarío Miranda-Pastoriza, Rodrigo Bernárdez, Jhonny Azuaje, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 5, 2024
Exploring Biginelli-based scaffolds as A<sub>2B</sub> adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agentsRubén Prieto-Díaz, Hugo Fojo-Carballo, Maria Majellaro, et al.
Journal of Medicinal Chemistry|January 24, 2022
Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A<sub>1</sub> AntagonistsCristina Val, Carlos Rodríguez-García, Rubén Prieto-Díaz, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
A<sub>2B</sub> adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer modelsApple Hui Min Tay, Rubén Prieto-Díaz, Shiyong Neo, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Pharmacological Research|November 10, 2021
Similarities and differences upon binding of naturally occurring Δ<sup>9</sup>-tetrahydrocannabinol-derivatives to cannabinoid CB<sub>1</sub> and CB<sub>2</sub> receptorsIu Raïch, Rafael Rivas-Santisteban, Alejandro Lillo, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 26, 2023
Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugsClaudia Gioé-Gallo, Sandra Ortigueira, José Brea, et al.
Journal of Medicinal Chemistry|June 24, 2020
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A<sub>2B</sub> Adenosine Receptor AntagonistsAna Mallo-Abreu, Rubén Prieto-Díaz, Willem Jespers, et al.
Journal of Medicinal Chemistry|June 10, 2021
Potent and Subtype-Selective Dopamine D<sub>2</sub> Receptor Biased Partial Agonists Discovered via an Ugi-Based ApproachAna Mallo-Abreu, Irene Reyes-Resina, Jhonny Azuaje, et al.
European Journal of Medicinal Chemistry|January 19, 2023
N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R)Giovanni Graziano, Pietro Delre, Francesca Carofiglio, et al.
Angewandte Chemie (International Ed. in English)|June 17, 2020
X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A<sub>2A</sub> Adenosine Receptor AntagonistsWillem Jespers, Grégory Verdon, Jhonny Azuaje, et al.
ACS Medicinal Chemistry Letters|February 18, 2022
Exploring Non-orthosteric Interactions with a Series of Potent and Selective A<sub>3</sub> AntagonistsDarío Miranda-Pastoriza, Rodrigo Bernárdez, Jhonny Azuaje, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 5, 2024
Exploring Biginelli-based scaffolds as A<sub>2B</sub> adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agentsRubén Prieto-Díaz, Hugo Fojo-Carballo, Maria Majellaro, et al.
Journal of Medicinal Chemistry|January 24, 2022
Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A<sub>1</sub> AntagonistsCristina Val, Carlos Rodríguez-García, Rubén Prieto-Díaz, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
A<sub>2B</sub> adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer modelsApple Hui Min Tay, Rubén Prieto-Díaz, Shiyong Neo, et al.
Pageof 3